抗NMDAR脑炎患者的长期认知、功能及患者报告结局
该项大规模横断面与前瞻性队列研究纳入92例抗NMDAR脑炎患者,发现认知评分在诊断后36个月内随时间改善(R=0.35,p=0.022),但36个月后仍有34%存在持续认知损害、65%至少一个认知域低于平均水平,尽管91%患者mRS≤2;患者自报情绪健康、社会功能、精力及生活质量均显著低于常模。
要点
- 认知恢复可持续至诊断后36个月,前6个月改善最明显(R=0.35,p=0.022)。
- 36个月后34%患者存在持续认知损害(z-score<-1.5 SD),65%至少一个认知域低于平均水平(<-1 SD)。
- 尽管91%患者mRS≤2,自报情绪健康、社会功能、精力及生活质量仍显著低于常模(p<0.001)。
核心结论
- 抗NMDAR脑炎的恢复可能持续3年,存在持续认知缺陷(尤其是记忆和语言)以及社会功能、精力水平和幸福感受损的风险。
研究设计与样本
- 大规模横断面与前瞻性队列研究,纳入全国性队列中年龄>16岁、病前独立、能完成认知测试和/或自报的患者,共92例(年龄29±2岁;77%女性)。
主要发现
- 认知评分随评估时间改善,持续至诊断后36个月(R=0.35,p=0.022),前6个月改善最明显;该结果在前瞻性患者(n=12)中可重现。
- 超过36个月(n=44)的患者中,34%存在持续损害(z-score<-1.5 SD),65%在一个或多个认知域得分低于平均水平(<-1 SD),而多数(91%)mRS≤2。
- 受影响最重的是记忆(平均-0.67±0.89 SD,p=0.25)和语言(-0.75±1.06 SD,p=0.23)。
- 自报主诉持续存在于情绪健康(平均72±25 SD vs 常模82±33 SD,p<0.001)、社会功能(73±26 SD vs 84±22 SD,p<0.001)、精力水平(57±19 SD vs 69±19 SD,p<0.001)和生活质量(0.85±0.14 SD vs 0.93±0.11 SD,p<0.001)。
- 许多患者未恢复学业/工作(30%)或需要调整(18%);恢复学业/工作与处理速度(-0.14±0.78 SD vs -0.84±1.05 SD,p=0.039)和幸福感(EuroQol 5 Dimensions 5 Levels中位数0.90 vs 0.81,p=0.016)相关。
临床怎么用
- 常用的结局指标mRS不能完全反映结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Anti-NMDA receptor (anti-NMDAR) encephalitis generally manifests in young adults. Although 80%-90% returns to independence, the majority experience persistent cognitive and psychosocial difficulties. Studies have demonstrated that cognitive recovery may continue for years; the temporal trajectory is largely unknown, as are factors influencing cognitive/psychosocial recovery. Objectives were to (1) describe the cognitive recovery trajectory, (2) assess self-reported outcomes, (3) identify factors relating to outcome, and (4) explore the relation between cognitive and self-reported outcomes, and participation. METHODS: We performed a large-scale cross-sectional and prospective cohort study. We addressed our nationwide cohort, provided they were (1) older than 16 years, (2) independent preillness, and (3) able to perform cognitive tests and/or self-report. Patients completed Patient-Reported Outcome Measures and neuropsychological assessments (memory, language, perception and construction, and attention and executive functions), and functional outcomes were established (modified Rankin Scale [mRS] score and return-to-work/-education). Outcomes were compared with references and between groups based on clinical characteristics and functional outcomes (T-tests for normalized data and nonparametric tests for patient-reported data). Recovery was visualized by plotting outcomes against time-of-assessment. RESULTS: We included 92 patients (age 29 ± 2 years; 77% female). Cognitive scores improved with time-of-assessment, up to 36 months after diagnosis (R = 0.35, p = 0.022), with the most enhanced improvement in the first 6 months. This result could be reproduced in prospective patients (n = 12). Beyond 36 months (n = 44), 34% of patients had a persistent impairment (z-score <-1.5 SD) and 65% scored below-average (<-1 SD) in 1 or more cognitive domains, despite a "favorable" outcome measured by mRS (≤2) in the majority (91%). Most affected were memory (mean -0.67 ± 0.89 SD, p = 0.25) and language (-0.75 ± 1.06 SD, p = 0.23). Self-reported complaints remained in emotional well-being (mean 72 ± 25 SD vs norm 82 ± 33 SD, p < 0.001), social functioning (73 ± 26 SD vs 84 ± 22 SD, p < 0.001), energy levels (57 ± 19 SD vs 69 ± 19 SD, p < 0.001), and quality of life (0.85 ± 0.14 SD vs 0.93 ± 0.11 SD, p < 0.001). Many patients did not resume school/work (30%) or needed adjustments (18%). Resuming school/work related to processing speed (-0.14 ± 0.78 SD vs -0.84 ± 1.05 SD, p = 0.039) and well-being (EuroQol 5 Dimensions 5 Levels median 0.90 vs 0.81, p = 0.016). DISCUSSION: Recovery from anti-NMDAR encephalitis may continue for 3 years, with risk of persisting cognitive deficits, notably in memory and language, and sequelae in social functioning, energy levels, and well-being. The frequently applied outcome measure mRS does not fully capture outcomes. Almost half of patients struggled resuming school/work, associated with cognitive deficits and well-being.
引用
- Brenner J, Ruhe CJ, Kulderij I, et al. Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis. Neurology. 2024. PMID: 39566012. doi:10.1212/WNL.0000000000210109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。